Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BW-20507 injection combined with pegylated interferon alfa in chronic hepatitis B virus infection
CTR20253050Phase 2Active
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BW-20507, pegylated interferon alpha in Chronic Hepatitis B (CHB), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
BW-20507pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20253050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253050.